Company Short-Term Debts: Impact BioMedical Inc (IBO)

Impact BioMedical Inc (IBO) relies on US laboratories, outsourcing production to third-party contractors to maintain flexibility. The asset's market valuation trend on GURU.Markets, where the indicator stands at 0.00, confirms an expansion phase for proprietary medical solutions with a focus on partnerships by 2026. Meanwhile, revenue volatility persists due to the focus on patent creation and irregular licensing payments.

Company Short-Term Loans and Borrowings: Impact BioMedical Inc (IBO) for 09/17/2024 - 10/29/2026

Summary analytical data breakdowns for Impact BioMedical, Inc. (IBO)

- price and consensus price forecast:
Price Chart Impact BioMedical|IBO - Consensus Target
- market capitalization data:
Market Capitalization Impact BioMedical Inc|IBO - Enterprise Value
- book capitalization data:
Accounting Value per Share Impact BioMedical|IBO - Accounting Value of Company|Market Value to Book Value Ratio impactbiomedinc.com|IBO - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Impact BioMedical Inc|IBO - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Impact BioMedical Inc|IBO - Aggregate Debt Obligations|Debts to Book Capitalization Impact BioMedical Inc|IBO - Long-Term Debt|Company Short-Term Debt Impact BioMedical
Analysis of all company metrics:Impact BioMedical, IBO

When assessing the long-term risks of Impact BioMedical Inc (IBO), investors must analyze current liabilities due within one year, which measure the volume of floating-rate loans sensitive to regulatory decisions. This trend determines the cost of servicing liabilities, which is critical for maintaining the stability of the holding structure that diversifies revenues from patent licensing in the fields of antivirals and sugar substitutes.

Competitor analysis for Impact BioMedical Inc

HLN: Company Short-Term Debt|KVUE - Company Current Liabilities|VRNA: Company Short-Term Debts|Company Short-Term Debts Jyong Bio|LGND - Company Current Liabilities|Company Short-Term Loans and Borrowings AMRX|Perrigo - Company Short-Term Debt|Short-Term Debt Alvotech S.A. ALVO|Company Current Liabilities Liquidia Technologies (LQDA)|Amount of Current Liabilities Galapagos Corp GLPG|Company Short-Term Debts ANI Pharmaceuticals (ANIP)|MNKD - Company Short-Term Loans and Borrowings|Company Short-Term Debts AMPH|PCRX (Pacira Pharmaceuticals) - Short-Term Debt|SPRY - Company Short-Term Debt|Company Short-Term Loans and Borrowings Theravance Corp|AQST (Aquestive Therapeutics) - Company Short-Term Debts|Short-Term Debt Volume SCPH (scpharmaceuticals.com)|Tectonic Therapeutic - Company Short-Term Debt|Tonix Pharma - Company Current Liabilities|Company Short-Term Debt SXT China|EPRX - Current Liabilities|BHST: Company Short-Term Debts|invizyne.com (EXOZ) - Company Short-Term Debts|Company Short-Term Debts ORMP|Company Current Liabilities Entera Bio Corp (ENTX)|Company Current Liabilities MindWalk|Amount of Current Liabilities ABVC BioPharma, Inc ABVC|Company Current Liabilities Cumberland Pharmaceuticals|Company Short-Term Loans and Borrowings quantumbiopharma.com QNTM|FGEN - Company Short-Term Debts|TELO - Company Short-Term Debt|ranitherapeutics.com - Company Short-Term Debts|SNYR (Synergy CHC) - Short-Term Debt Volume|Company Short-Term Debt RLYB (Rallybio Corp)|Short-Term Debt LEXX|Company Short-Term Debt PULM (Pulmatrix)|Company Current Liabilities ftzy.com.cn (PTHL)|APM: Company Short-Term Debts|Short-Term Debt Lyra Therapeutics Inc LYRA|TNF Pharma (TNFA) - Company Short-Term Debts|YCBD - Company Short-Term Indebtedness|PainReform - Company Short-Term Debts|Altamira Therapeutics Ltd. (CYTO) - Short-Term Debt Volume|Company Short-Term Debts LIPO|Company Current Liabilities OptiNose Corp|Company Short-Term Debts PIRS|Company Short-Term Debts PROC (procapsgroup.com)|Company Short-Term Debt Petros Pharmaceuticals, Inc. PTPI|QLI - Company Short-Term Debt|Company Current Liabilities ACELYRIN, Inc. (SLRN)|TFFP - Company Short-Term Loans and Borrowings